| CDR | calcium-dependent regulator; clinical dementia rating; complementary determining region; computerize... |
|---|---|
| CKI | cyclin-dependent kinase inhibitor |
| CSD | carotid sinus denervation; cat scratch disease; combined system disease; conditionally streptomycin ... |
| DDP | cisplatin; density-dependent phosphoprotein; difficult denture patient; digital data processing; dis... |
| dep | dependent; deposit |
| type II diabetes | <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop. (05 Mar 2000) |
|---|---|
| juvenile diabetes | <endocrinology> A severe metabolic disorder which has an abrupt onset before the age of twenty. In it, an insulin deficiency prevents the body from using carbohydrates properly and forces it to rely mainly on protein metabolism. Treatment of the disease includes strict dietary regulation and mandatory insulin injections. (09 Oct 1997) |
| juvenile onset diabetes | A form of diabetes which has its onset in childhood. Also referred to as type I diabetes, juvenile onset diabetes or insulin-dependent diabetes. The exact cause is unknown but genetic factors seem to play a major role. Symptoms include excessive thirst, increased urination, weight loss (despite increased appetite), nausea, vomiting, fatigue and absent menstruation. Treatment includes education and regular insulin therapy. See: insulin-dependent diabetes mellitus (22 Sep 2002) |
| ketosis-prone diabetes | Type I or juvenile diabetes mellitus, in which inadequate treatment leads to development of ketoacidosis. (05 Mar 2000) |
| ketosis-resistant diabetes | Type II or adult onset diabetes mellitus, in which episodes of ketoacidosis rarely occur. (05 Mar 2000) |
| latent diabetes | A mild form of diabetes mellitus in which the patient displays no overt symptoms, but displays certain abnormal responses to diagnostic procedures, such as an elevated fasting blood glucose concentration or reduced glucose tolerance. Synonym: chemical diabetes. (05 Mar 2000) |
| lipoatrophic diabetes | Loss of subcutaneous fat, which may be total, congenital, and associated with hepatomegaly, excessive bone growth, and insulin-resistant diabetes. Synonym: Lawrence-Seip syndrome, lipoatrophia, lipoatrophic diabetes. Origin: G. Lipos, fat, + a-, priv. + trophe, nourishment (05 Mar 2000) |
| lipogenous diabetes | Diabetes and obesity combined. (05 Mar 2000) |
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |